Monthly
US$200
Billed every month
Sodium Nitroprusside Injection(硝普钠注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 3 applicationsAccepted: 1 applicationNo longer listed under review: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders12View records ↓
Under-review filings15View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers10View records ↓
API companies with A status17View records ↓
Chemical-drug catalogue
Loaded records: 12 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 12 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Dr. Reddy’s Laboratories Limited | Dr. Reddy’s Laboratories Limited | 国药准字HJ20260086 | 2026/09/29 | 2ml:50mg[按Na2[Fe(CN)5NO] ·2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Caplin Steriles Limited | Caplin Steriles Limited | 国药准字HJ20260085 | 2026/09/22 | 2ml:50mg[按Na2Fe(CN)5NO·2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20265876 | 2026/09/08 | 2ml：50mg[按Na2Fe(CN)5NO？2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京世桥生物制药有限公司 | 北京世桥生物制药有限公司 | 国药准字H20265595 | 2026/08/04 | 2ml︰50mg[按Na2[Fe(CN)5NO]·2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 嘉实（湖南）医药科技有限公司 | 康普药业股份有限公司 | 国药准字H20264923 | 2026/06/23 | 2ml:50mg [按Na2Fe(CN)5NO·2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华夏生生药业（北京）有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20264379 | 2026/05/19 | 2ml:50mg[按Na2Fe(CN)5NO·2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20264118 | 2026/04/21 | 2ml：50mg[按Na2Fe(CN)5NO·2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都瑞尔医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20263476 | 2026/02/25 | 2ml∶50mg（按Na2[Fe(CN)5NO]·2H2O计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都新恒创药业有限公司 | 成都新恒创药业有限公司 | 国药准字H20249215 | 2024/10/29 | 2ml:50mg（按Na<sub>2</sub>Fe(CN)<sub>5</sub>NO·2H<sub>2</sub>O计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南普利制药股份有限公司 | 海南普利制药股份有限公司 | 国药准字H20223226 | 2022/04/12 | 2ml:50mg[按Na2[Fe(CN)5NO] ·2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南恒生制药股份有限公司 | 湖南恒生制药股份有限公司 | 国药准字H20256405 | 2025/12/30 | 2ml:50mg [按Na2Fe(CN)5NO·2H2O计] | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 康普药业股份有限公司 | 康普药业股份有限公司 | 国药准字H20266289 | 2026/10/20 | 2ml:50mg（按Na2Fe(CN)5NO·2H2O计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 10 distinct approval numbers and 10 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京世桥生物制药有限公司 | 国药准字H20265595 | 2ml:50mg[按Na2Fe(CN)5NO·2H2O计] | Category A (甲) | XC02DDX070B002010100123 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20264118 | 2ml:50mg(按Na₂Fe(CN)₅NO·2H₂O计) | Category A (甲) | XC02DDX070B002010101066 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20265876 | 2ml:50mg[按Na₂Fe(CN)₅NO·2H₂O计] | Category A (甲) | XC02DDX070B002010104145 | NHSA |
| 湖南恒生制药股份有限公司 | 国药准字H20256405 | 2ml:50mg [按Na₂Fe(CN)₅NO·2H₂O计] | Category A (甲) | XC02DDX070B002010104900 | NHSA |
| 海南普利制药股份有限公司 | 国药准字H20223226 | 2ml:50mg[按Na₂[Fe(CN)₅NO]·2H₂O计] | Category A (甲) | XC02DDX070B002010105801 | NHSA |
| 成都新恒创药业有限公司 | 国药准字H20249215 | 2ml:50mg(按Na₂Fe(CN)₅NO•2H₂O计) | Category A (甲) | XC02DDX070B002010109552 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20264379 | 2ml:50mg[按Na₂Fe(CN)₅NO·2H₂O计] | Category A (甲) | XC02DDX070B002010109910 | NHSA |
| 嘉实(湖南)医药科技有限公司 | 国药准字H20264923 | 2ml:50mg [按Na₂Fe(CN)₅NO·2H₂O计] | Category A (甲) | XC02DDX070B002010183048 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20263476 | 2ml:50mg(按Na₂Fe(CN)₅NO·2H₂O计) | Category A (甲) | XC02DDX070B002010184534 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20263476 | 2ml:50mg(按Na₂Fe(CN)₅NO·2H₂O计) | Category A (甲) | XC02DDX070B002010284534 | NHSA |
| Caplin Steriles Limited | 国药准字HJ20260085 | 2ml:50mg[按Na₂Fe(CN)₅NO•2H₂O计] | Category A (甲) | XC02DDX070B002010185310 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 15 filings and 14 distinct first applicants.
Generic 15
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 南京海纳制药有限公司 | CYHS2503804 | Generic | 2025/10/28 | Not stated by source | CDE |
| 扬州中宝药业股份有限公司 | CYHS2600947 | Generic | 2026/04/24 | Not stated by source | CDE |
| 丹东医创药业有限责任公司 | CYHS2602475 | Generic | 2026/10/10 | Not stated by source | CDE |
| 上海禾丰制药有限公司 | CYHS2503741 | Generic | 2025/10/21 | Not stated by source | CDE |
| 四川奇裕医药科技有限公司;康普药业股份有限公司 | CYHS2503444 | Generic | 2025/09/18 | Not stated by source | CDE |
| 华润双鹤药业股份有限公司 | CYHS2503066 | Generic | 2025/08/20 | Not stated by source | CDE |
| 四川健林药业有限责任公司;四川科瑞德制药股份有限公司 | CYHS2502341 | Generic | 2025/07/02 | Not stated by source | CDE |
| 广州世济医药科技有限公司;广东星昊药业有限公司 | CYHS2502228 | Generic | 2025/06/20 | Not stated by source | CDE |
| 海南倍特药业有限公司 | CYHS2502213 | Generic | 2025/06/20 | Not stated by source | CDE |
| 仁合益康汇泽药业河北有限公司 | CYHS2502175 | Generic | 2025/06/18 | Not stated by source | CDE |
| 河北一品制药股份有限公司 | CYHS2502011 | Generic | 2025/06/06 | Not stated by source | CDE |
| 山东齐都药业有限公司 | CYHS2501982 | Generic | 2025/06/05 | Not stated by source | CDE |
| 山东齐都药业有限公司 | CYHS2501981 | Generic | 2025/06/05 | Not stated by source | CDE |
| 海南海和制药有限公司;海南灵康制药有限公司 | CYHS2501159 | Generic | 2025/03/25 | Not stated by source | CDE |
| 海南爱科制药有限公司;海南灵康制药有限公司 | CYHS2500578 | Generic | 2025/02/06 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 17 companies with A status and 3 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 硝普钠 | 湖南复瑞生物医药技术有限责任公司 | Y20260000486 | I | Exact ingredient | 2026/08/18 | CDE |
| 硝普钠 | 绪必迪药业（沧州）有限公司 | Y20250001347 | I | Exact ingredient | 2025/12/15 | CDE |
| 硝普钠 | 河北安健成益医药科技有限公司 | Y20250000236 | A | Exact ingredient | 2026/09/11 | CDE |
| 硝普钠 | 安徽普利药业有限公司 | Y20240001218 | A | Exact ingredient | 2026/03/26 | CDE |
| 硝普钠 | 山东川成医药有限公司 | Y20240000799 | A | Exact ingredient | 2026/10/31 | CDE |
| 硝普钠 | 双鹤药业（商丘）有限责任公司 | Y20240000362 | A | Exact ingredient | 2025/08/22 | CDE |
| 硝普钠 | 湖南恒生制药股份有限公司 | Y20240000094 | A | Exact ingredient | 2025/08/26 | CDE |
| 硝普钠 | Azico Biophore India Pvt Ltd | Y20230001195 | A | Exact ingredient | 2026/08/28 | CDE |
| 硝普钠 | 河南中帅药业有限公司 | Y20220001337 | A | Exact ingredient | 2024/09/29 | CDE |
| 硝普钠 | 成都新恒创药业有限公司 | Y20220001181 | A | Exact ingredient | 2025/12/20 | CDE |
| 硝普钠 | 湖南华纳大药厂手性药物有限公司 | Y20210000083 | A | Exact ingredient | 2026/04/14 | CDE |
| 硝普钠 | 三门峡赛诺维制药有限公司 | Y20190009710 | A | Exact ingredient | 2025/03/14 | CDE |
| 硝普钠 | 湖北葛店人福药业有限责任公司 | Y20190007504 | A | Exact ingredient | 2025/03/01 | CDE |
| 硝普钠 | 华润双鹤药业股份有限公司 | Y20190005092 | A | Exact ingredient | 2025/07/29 | CDE |
| 硝普钠 | 康普药业股份有限公司 | Y20190004573 | A | Exact ingredient | 2026/03/21 | CDE |
| 硝普钠 | 上海迪冉郸城制药有限公司 | Y20190004349 | A | Exact ingredient | 2024/11/01 | CDE |
| 硝普钠 | 北京世桥生物制药有限公司 | Y20190003626 | A | Exact ingredient | — | CDE |
| 硝普钠 | 丹东医创药业有限责任公司 | Y20190002726 | A | Exact ingredient | 2025/05/22 | CDE |
| 硝普钠 | 海南普利制药股份有限公司 | Y20190000020 | A | Exact ingredient | 2024/03/14 | CDE |
| 硝普钠 | 三门峡赛诺维制药有限公司 | Y20170002000 | A | Exact ingredient | 2022/10/18 | CDE |
| 硝普钠 | 河北一品制药股份有限公司 | Y20260000897 | I | Exact ingredient | 2026/10/30 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03Marketing application approved
山西九康医药科技有限公司
CYHS2501176 · 国药准字H20266490
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 45 ↗ -
2026/10/31No longer listed under review
成都欣捷高新技术开发股份有限公司;四川美大康佳乐药业有限公司
CYHS2501096
Fact date: 2026/10/31 · Site observation date: 2026/10/31
Accepted: 2025/03/18
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/31No longer listed under review
成都欣捷高新技术开发股份有限公司;四川美大康佳乐药业有限公司
CYHS2501095
Fact date: 2026/10/31 · Site observation date: 2026/10/31
Accepted: 2025/03/18
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/20Marketing application approved
中润药业有限公司
CYHS2501180 · 国药准字H20266312
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 44 ↗ -
2026/10/20Marketing application approved
康普药业股份有限公司
CYHS2500903 · 国药准字H20266289
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
Same-name approval records dated before this approval were found, with company roles identified below:
- Manufacturer record / approval date · 国药准字H20264923 · 2026/06/23 · View source
-
2026/10/10Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Sodium Nitroprusside Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy